Key Comorbid Conditions that Are Predictive of Survival among Hemodialysis Patients

被引:68
作者
Miskulin, Dana [1 ]
Bragg-Gresham, Jennifer [2 ]
Gillespie, Brenda W. [3 ]
Tentori, Francesca [2 ]
Pisoni, Ronald L. [2 ]
Tighiouart, Hocine [4 ]
Levey, Andrew S. [1 ]
Port, Friedrich K. [2 ]
机构
[1] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA
[2] Arbor Res Collaborat Hlth, Ann Arbor, MI USA
[3] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
[4] Tufts Med Ctr, Inst Clin Res & Hlth Policy, Boston, MA 02111 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 4卷 / 11期
关键词
ESRD PATIENTS; MORTALITY; INDEX; OUTCOMES; TIME;
D O I
10.2215/CJN.00640109
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Abstracting information about comorbid illnesses from the medical record can be time-consuming, particularly when a large number of conditions are under consideration. We sought to determine which conditions are most prognostic and whether comorbidity continues to contribute to a survival model once laboratory and clinical parameters have been accounted for. Design, setting, participants, & measurements: Comorbidity data were abstracted from the medical records of Dialysis Outcomes and Practice Pattern Study (DOPPS) I, II, and III participants using a standardized questionnaire. Models that were composed of different combinations of comorbid conditions and case-mix factors were compared for explained variance W) and discrimination (c statistic). Results: Seventeen comorbid conditions account for 96% of the total explained variance that would result if 45 comorbidities that were expected to be predictive of survival were added to a demographics-adjusted survival model. These conditions together had more discriminatory power (c statistic 0.67) than age alone (0.63) or serum albumin (0.60) and were equivalent to a combination of routine laboratory and clinical parameters (0.67). The strength of association of the individual comorbidities lessened when laboratory/clinical parameters were added, but all remained significant. The total R-2 of a model adjusted for demographics and laboratory/clinical parameters increased from 0.13 to 0.17 upon addition of comorbidity. Conclusions: A relatively small list of comorbid conditions provides equivalent discrimination and explained variance for survival as a more extensive characterization of comorbidity. Comorbidity adds to the survival model a modest amount of independent prognostic information that cannot be substituted by clinical/laboratory parameters. Clin J Am Soc Nephrol 4: 1818-1826, 2009. doi: 10.2215/CJN.00640109
引用
收藏
页码:1818 / 1826
页数:9
相关论文
共 21 条
[1]  
[Anonymous], 2006, USRDS 2006 ANN DAT R
[2]   A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients [J].
Beddhu, S ;
Bruns, FJ ;
Saul, M ;
Seddon, P ;
Zeidel, ML .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (08) :609-613
[3]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[4]  
Department of Health and Human Services, END STAG REN DIS MED
[5]   Effect of dialysis dose and membrane flux in maintenance hemodialysis. [J].
Eknoyan, G ;
Beck, GJ ;
Cheung, AK ;
Daugirdas, JT ;
Greene, T ;
Kusek, JW ;
Allon, M ;
Bailey, J ;
Delmez, JA ;
Depner, TA ;
Dwyer, JT ;
Levey, AS ;
Levin, NW ;
Milford, E ;
Ornt, DB ;
Rocco, MV ;
Schulman, G ;
Schwab, SJ ;
Teehan, BP ;
Toto, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2010-2019
[6]   Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients [J].
Fried, L ;
Bernardini, J ;
Piraino, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (02) :337-342
[7]  
Goodkin D. A., 1999, Journal of the American Society of Nephrology, V10, p242A
[8]   Association of achieved dialysis dose with mortality in the Hemodialysis Study: An example of "dose-targeting bias" [J].
Greene, T ;
Daugirdas, J ;
Depner, T ;
Allon, M ;
Beck, G ;
Chumlea, C ;
Delmez, J ;
Gotch, F ;
Kusek, JW ;
Levin, N ;
Owen, W ;
Schulman, G ;
Star, R ;
Toto, R ;
Eknoyan, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (11) :3371-3380
[9]   Adapting the Charlson Comorbidity index for use in patients with ESRD [J].
Hemmelgarn, BR ;
Manns, BJ ;
Quan, H ;
Ghali, WA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (01) :125-132
[10]  
Iezzoni LI., 1997, RISK ADJUSTMENT MEAS, V2nd